The French startup plans to offer a precommercial version of its hardware platform to beta testers as early as the end of 2019.
The collaboration will focus on the development of a bespoke silicon array to enable high-throughput production of high-fidelity gene-length DNA.
Agilent said it has uncovered new and relevant facts in its intellectual property lawsuit against Twist and its Founder and CEO Emily LeProust.
The synthesis method will be incorporated into the silicon array the company developed to produce DNA at scale.
In a proof-of-concept study published in Nature Biotechnology this week, the team demonstrated that it could enzymatically synthesize 10-mer oligonucleotides.
The deals cover the company's synthetic DNA and next-generation sequencing products, including its newly launched target enrichment line.
The grant money will be provided through the EC's Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.
The company, which recently entered the next-generation sequencing sample prep market, said it has raised $259 million since it was founded in 2013.
Twist Bioscience wants to shrink DNA synthesis to smaller and smaller volumes, possibly enabling DNA storage, according to the San Francisco Chronicle.
The company, which was founded in 2016, said it would use the funding to further develop its core gene synthesis platform.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.